CompletedNot Applicable

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Japan48 participantsStarted 2016-07-15

Plain-language summary

The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.

Who can participate

Age range14 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female and male pediatric patients (less than 15 years old) with a diagnosis of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas aeruginosa. * Patients for whom the decision to initiate treatment with Ciproxan injection was made as per investigator's routine treatment practice. Exclusion Criteria: * N/A

What they're measuring

Number of musculoskeletal adverse events.

Timeframe: Up to 12 months

Trial details

NCT IDNCT02555059

SponsorBayer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-12-17

View on ClinicalTrials.gov More Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax trials